Vanguard Group’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History
Bought
Maintained
Sold
Vanguard Group's AST.WS Position: Q3 2017 in Review
Vanguard Group sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 89,777 shares — an estimated $45K sold.
Vanguard Group first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $49K in Q4 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.
- Vanguard Group reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
- Vanguard Group sold 89,777 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $45K.
- Vanguard Group first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
- Vanguard Group's Asterias Biotherapeutics Warrants position peaked at $49K in Q4 2016.
- 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.
Based on Vanguard Group's 13F filing for Q3 2017, filed 14 Nov 2017.